TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinical Improvement by Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: admission to intensive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of post-operative opioid induced constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of surgeries categorized as major or minor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance at the manual task (Nine Hole Peg Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rescue respiratory resuscitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of ICU Transfers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Metal Ion Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to anastrozole treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of infectious complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in CGI-S score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve From Time Zero to 25 Hours Postdose (AUC25) of Docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of anti-mullerian hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Antral Follicle Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Patients That Underwent Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of CDI
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of Ad sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Ki-67 Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: White matter hyperintensities Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grey Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lacunar infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Small vessel microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Knee Extension Isometric Strength (Peak Torque)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Residual Limb Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Residual Limb Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dialysis symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: A2M levels in plasma and synovium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncology patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Differential function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly developed scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Genotype the 4 PKLR intron-2 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analysis of PK-R transcriptome in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of 2,3-DPG, ATP and pyruvate kinase activities with PKLR intron-2 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDQ-7 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients who develop tolerance post autologous HSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post extubation respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GVHD mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients maintaining temperature below 36.0°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Simple Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Choice Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognition as assessed by the ADAS-Cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognition as assessed by the ADCS-ADL total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognition as assessed by the CDR-SOB total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognition as assessed by the MMSE total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastrointestinal Quality of Life GIQLI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Had PCR Confirmed SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported CAT-score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of Obesity Hypoventilation Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of cyclosporine on dry eye syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemispheric Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Fields Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surgical and healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of MoCA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythromycin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rivaroxaban urine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Related Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment related adverse events and cardiac disease after radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Healing efficacy of Rebamipide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained attention composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe complications after PCI
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Quarterly Visits In Which an STI Was Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relapse of CIDP Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plasma C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in levels of D-Dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in levels of Fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in levels of PAI-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Energy delivered (% of caloric target)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protein delivered (% of caloric target)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Start of enteral feeding after ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Presence or absence of concussion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in transcutaneous CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Joint Synovitis as Measured by GLOESS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety and Tolerability by means of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RP2D) of VCN-01
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrin clot structure and function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrin permeation analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low density lipoprotein fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidised low density lipoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: energy expenditure after weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunity index of seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality Adjusted Survival (QAS)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline OA pain in the target knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Polysomnographic Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in presence of reticulation, erythema and ulceration on mucosal surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of RAS lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain intensity and discomfort in OLP patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life change in OLP patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in pain intensity and discomfort in RAS patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life change in RAS patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Solicited Injection Site Erythema and Tenderness
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline ankle stability by Cumberland Ankle Instability Tool (CAIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline dynamic ankle stability by Y-balance test (YBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in pain by visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Accurate calculation of intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cataract grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: peak lactate/pyruvate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lactate/pyruvate area under curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apparent rate of constant metabolic flux of HP 13C-pyruvate to lactate (kPL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Significant proteinuria rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fluid intelligence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ablation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on frailty status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhalational anaesthetic drug requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion in primary cervical tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy intake in kcal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prostate cancer screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: peak percent change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) signal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adolescent Marijuana Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine prostacyclin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine thromboxane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boney consolidation of the fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma NGAL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-report adherence to exercise and diet prescriptions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sickness absence (analysed as work participation)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of participants completing vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in Severe Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MRI T1 signal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of all Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cranial blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Flexion-relaxation Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Breast pump vacuum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ketone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjects Global Assessment of Therapy (SGAT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median Progression-free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Progression-free Survival at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Clinical success rate of filter implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sonographic evidence of a thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seven day abstinence from tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Treatment of Bleeding Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-reported Alcohol Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of anterior vitrectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Time from discharge to first readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to the Protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Opioid Free Discharge
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Low energy availability for females
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating disorder examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight regulation strategies
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Epithelialization of the examined wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular system function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Musculoskeletal system function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seattle Angina Questionnaire (SAQ-7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Health Questionnaire (PHQ-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aesthetic breast scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Sleep Continuity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Gd Level from 24-hour Urine Samples Following Calcium DTPA Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Gd Level from 24-hour Urine Samples Following Zinc DTPA Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evans Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of successful triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescued dose of morphine injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete cell cycle arrest (CCCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ratio of reduced to oxidized glutathione in blood erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Ocular Surface Disease Index (OSDI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Who Achieved at Least 5*10^6 CD34+ Cells Per Kilogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to 10 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Alcohol Use (Heavy Drinking Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Use (Drinking Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Use (Drinks Per Drinking Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Use (Drinks Per Week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natalizumab Concentrations in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes